Modified FOLFOX-4 as first-line and salvage treatment in advanced gastric cancer

Hepato-Gastroenterology

Volumn 58, Issue 105, 2011, Pages 251-256

  Baek, Yang Hyun ^a   Choi, Seok Reyol ^a   Jang, Jin Seok ^a   Roh, Myung Hwan ^a   Lee, Jong Hun ^a   Won, Jong Jin ^a   Lee, Chang Min ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

AGC; First line chemotherapy; Modified FOLFOX 4; Prognostic factor; Salvage treatment

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER DISEASE; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SALVAGE THERAPY; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79955028974     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl J Med 1995; 333:32-41.
2. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24:2903-2909. (Pubitemid 46630593)
3. Dickson JL, Cunningham D: Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol 2004; 16:255-263.
4. Kim NK, Park YS, Heo DS, suh C, Kim SY, Park KC, Kang YK, et al: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71:3813-3818.
5. Wilke H, Wils J, Rougier P: Preliminary analysis of a randomized phase IH trial of FAMTX versus cisplatin/5-FU in advanced gastric cancer. A trial of the EORTC gastrointestinal tract cancer cooperative group and AIO. Proc Am Soc Clin Oncol 1995; 14:206.
6. Bleiberg H, de Gramont A: Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998;25:32-39. (Pubitemid 28248699)
7. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al: Leucovorin and fiuorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
8. Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, et al: Phase II study of oxaliplatin, fiuorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20:4543-4538.
9. De vita F, Orditura M, Matano E, Bianco R, Carlomaqno C, Infusino S, et al: A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 92:1644-1649.
10. Cavanna L, Artioli F, Codiqnola C, Lazzaro A, Rizzi A, Gamboni A, et al: Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol 2006; 29:371-375. (Pubitemid 44201990)
11. Kim DY, Kim JH, Lee SH, Kim TY, Heo DS, Bang YJ, Kim NK: Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 2003; 14:383-387. (Pubitemid 36367414)
12. Seo HY, Kim DS, Choi YS, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, et al: Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. Cancer Chemother Pharmacol 2009; 63:433-439.
13. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al: Randomized trial comparing epirubicin, cisplatin, and fiuorouracil versus fiuorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15:261-267.
14. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al: Long-term survival after epirubicin, cisplatin and fiuorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80:269-272. (Pubitemid 29210117)
15. Liu ZF, Guo QS, Zhang XQ, Yang XG, Guan F, Fu Z, Wang MY: Biweekly oxaliplatin in combination with continuous infusional 5-fiuorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am J Clin Oncol 2008:31:259-263.
16. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, Louvet C, Gespach C: Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer drugs 1997;8:876-885. (Pubitemid 27487802)
17. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, et al: Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol 2008; 61:105-111. (Pubitemid 47512632)
18. Jolivet J: Role of leucovorin dosing and administration schedule. Eur J Cancer 1995; 31A:1311-1315.
19. Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ: A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol 2007;46:336-341. (Pubitemid 46628612)
20. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, et al: Phase II trial of biweekly infusional fiuorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 15:658-663. (Pubitemid 41102130)